#

Gout

  • Compensation to be determined
  • 13 visits (enrollment open)
#

Between 19+ Years

#
Male or Female
#
Smoker & Non-Smoker

Description

A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants with Gout.

Gout is one of the most common types of inflammatory arthritis and is characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in the joints, which are caused by the deposition of urate (uric acid) crystals in the joints. The most important risk factor for the development of gout is chronically elevated levels of uric acid in the blood; treatment of gout is focused on decreasing levels of uric acid.

The study will last approximately 34 weeks (about 8 months) for each subject, and subject will need to come to the study center up to 17 times.

Is this not what you are looking for?
Check out our other studies.

Related Studies

#

Chronic Idiopathic Urticaria

  • Compensation to be determined
  • 13 clinic visits including 3 safety follow-up visits
#
Between 18 - 75 Years

#
Male or Female
#
Smoker & Non-Smoker
#

Small Cell Lung Cancer

  • Compensation to be determined
  • Clinical visits 24
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

Depression (ALTO)

  • Compensation to be determined
  • The total number of visits is 12 with 5 visits in clinic and 7 remote visits
#
Between 18 - 65 Years

#
Male or Female
#
Smoker & Non-Smoker
© 2024 Access Research Institute. All Rights Reserved